BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: Cardiology stents are tubes placed in the coronary artery to clear artery blockages or coronary artery stenosis.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Sports medicine, also called sports & exercise medicine, is a specialty, which helps in the management and treatment of sports and exercise-related injuries.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Devices used for point-of-care molecular diagnostics are portable, compact, and self-contained diagnostic devices that can perform multiple analytical functions.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Rise in automation in laboratories, technological advancements in laboratory information systems, need for regulatory compliance, and increase in R&D spending are the key drivers of the global laboratory information systems market.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Infusion pumps are medical devices utilized by physicians and patients to deliver medications, fluids, and nutrition into the patient’s body in a controlled manner.

Velocity Clinical Research, the leading integrated research site organisation, announces it has acquired its first European site, Clinical Research Hamburg, in Germany for an undisclosed amount.

PCI Pharma Services, a leading global contract development and manufacturing organization, announced a significant expansion of its world-class facility in Tredegar, Wales, UK, designed to help keep pace with the market growth of powerful, targeted oncology therapies.

The shareholders of Biovica International AB, reg. no. 556774-6150, are hereby invited to the annual general meeting on Wednesday 31 August 2022.

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022.

IDEAYA Biosciences, Inc. announced it has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397, its investigational, potential best-in-class, small molecule MAT2A inhibitor, with Amgen’s AMG 193, an investigational small molecule MTA-cooperative inhibitor of PRMT5, in a Phase 1 clinical trial.